



Metal complexes of Nimesulide; synthesis, characterization and *in-vitro* biological screening

Akhtar S¹, Khan MA², Shahid K¹, Akhtar H²

¹Riphah Institute of Pharmaceutical Sciences, Riphah International University, 7th Avenue, Sector G-7/4, Islamabad, 44000, Pakistan,
²Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, H-12 Sector, Islamabad, 44000, Pakistan

Address for Correspondence
Samar Akhtar
E-mail : samarasif@hotmail.com

Received: 20-06-2014
Review completed: 04-07-2014
Accepted: 07-07-2014

ABSTRACT

Medicinal importance of metals and their compounds were recognised centuries ago but changed the direction of research of many drug discovery groups after the recognition of promising anticancer ability of Cisplatin. Now many of the metal based drugs have entered the phase of clinical trials. Discovery of new therapeutic moieties require huge funding and efforts, so derivatization of the already existing drugs is the need of the day to investigate their other pharmacological aspects. Keeping the same in mind zinc, copper, iron and antimony complexes of nimesulide were synthesized. These complexes were characterized by elemental analysis, FT-IR, ¹H and ¹³C NMR spectral studies antibacterial and antifungal assays. Interestingly, the results of *in-vitro* biological screening of the synthesized complexes revealed that the metal complexes are more active than the parent drug nimesulide.

Key words: Metal Complexes, Nimesulide, IR and NMR spectroscopy, *In-vitro* Biological screening

Access this article online

QR Code



Website:
www.ijrpsonline.com

INTRODUCTION

Nimesulide belongs to the sulphonamide class of non-steroidal anti-inflammatory drugs (NSAID)¹. It is cyclooxygenase-2 inhibitor and clinically advised in the states of fever, pain and inflammation^{2,3}. In addition to the above mentioned uses it is also recommended in vascular diseases, arthritic conditions, post-operative and cancer related pains⁴. Recently, syntheses of novel silver complex of nimesulide have been reported with enhanced antibacterial activity against Gram-negative and Gram-positive pathogenic bacterial strains⁵. Metallopharmaceuticals have been able to exhibit unique physical and chemical properties and potential therapeutic outputs. Metals have the capability to form stable complexes with many of the already known pharmacologically active moieties with enhanced properties⁶. Metals and their compounds have shown versatile medicinal properties throughout history and were used as antibacterial, antifungal, antiviral, antioxidant, anti-diabetic, anti-protozoal and anticancer agents⁷. Copper, zinc and iron are considered to be essential part of human body, required in

specific amounts for proper growth and performance of all the vital functions of life smoothly. Their deficiency in body causes various disorders and excess may lead to toxic effects⁸. Incorporation of these trace minerals with pharmacologically active molecules have led to the further improvement of the pharmacological profile of the reacting biologically active molecule for example, copper complexes of various non-steroidal anti-inflammatory drugs have been reported as potential anti-inflammatory agents with better efficacy and reduced adverse effects⁹. There is a report in the literature showing synthesis, gastrointestinal toxicity and anti-inflammatory effects of copper and zinc complexes of Indomethacin with less toxicity and unaltered anti-inflammatory action¹⁰. Zinc upon complexation with drug Kefzol (beta-lactam antibiotic) have improved the potency of the drug¹¹. Iron has also exhibited promising effects, when co-ordinated with therapeutic agents for instance its complexes has resulted in elevated antitumor activity of Adriamycin and daunorubicin¹². Antimony and its compound are known for their anti-leishmanial effects, researchers are also

working to unveil its other medicinal specialities with focus in the discipline of oncology¹³. Recently antimony (III) chloride complexes with sulphonamides and Tosyl sulphonamide derivatives were reported with enhanced antibacterial activity¹⁴. Keeping in mind the above mentioned hypothesis that metal complexation will produce unique or enhanced biological properties, Cu (II), Zn (II), Fe (III) and Sb (III) complexes of nimesulide were synthesized, spectroscopically characterized and biologically assessed.

MATERIALS AND METHOD

Metal salts, reagents and other required chemicals were purchased from Sigma Aldrich. Glassware was washed and dried at 120°C. Nimesulide was obtained as a gift from pharmaceutical industry. FT-IR was done on using BrukerIR spectrophotometer (4000-400cm⁻¹). ¹H, and ¹³C nuclear magnetic resonance spectra were recorded on a

Bruker AV400RG NMR spectrophotometer. Elemental analysis was performed using LECO-183 CHN analyser.

Synthesis of Copper complex (N-C)

Copper complex of ribavirin was synthesized using copper (II) acetate 1mmol solution in methanol. The solution of drug (Nimesulide) 1mmol was also made in methanol 15ml. The pH was optimized to 7 with the help of triethylamine. The solution was continuously stirred for four hours and then refrigerated overnight. The product was obtained after filtration, washed with methanol and dried in vacuum¹⁵.

Synthesis of Zinc complex (N-Z)

10ml methanolic solutions of Zinc chloride 2mmol and Nimesulide 2mmol were prepared separately. Then the solution of the metal salt and the drug (nimesulide) were mixed together in a round bottom flask with continuous stirring. The mixture was heated to 60°C for one hour. The product was filtered after cooling down the reaction mixture. Resulting product was washed with ethanol and dried¹⁶




Figure 1: Synthetic scheme of Metal Complexes of Nimesulide.

Metal complexes of nimesulide with Zn(II), Cu(II), Fe(III) and Sb(III) were synthesized with the given protocols and their physicochemical characteristics are given below.

Nimesulide (N):

Yellow solid, melting point 147°C, IR spectroscopy $\nu(4000-400\text{ cm}^{-1})$: $\nu(\text{C-H})$ 3030s, $\nu(\text{N-H})$ 3279s, $\nu(\text{CH=CH})$ 1487m, $\nu(\text{O=S=O})$, stretching) 1334s, $\nu(\text{C-O})$ 1247s, $\nu(\text{C-N})$ 1151m. ¹H-NMR (400MHz, CDCl₃) δ (ppm) 7.26m; 7.18m (–C₆H₅), 7.54m; 7.16m; 6.76s (–C₆H₃NO₂–), 3.12s (CH₃SO₂), 3.5s (–NH–) ¹³C NMR (100MHz, CDCl₃) δ (ppm) 136.06(C-1), 119.99(C-2), 119.74(C-3), 143.56 (C-4), 112.87 (C-5), 147.92 (C-6), 155.5(C-7), 121.55(C-8, C-12) 130.8 (C-9,C-11) 125.34 (C-10) and 41.34 (C-13).

Cu (II) complex of Nimesulide (N-C)

Yield 70 %, green solid, melting point 180 °C, FT-IR $\nu(4000-400\text{ cm}^{-1})$: $\nu(\text{CH=CH})$ 1488m, $\nu(\text{O=S=O})$, Stretching), 1339s, $\nu(\text{C-O})$ 1247s, $\nu(\text{C-N})$ 1151m, $\nu(\text{M-N})$ 517m, ¹H NMR (400MHz, CDCl₃) δ (ppm) 7.57m; 7.39m; 7.28m (–C₆H₅), 7.7d; 6.92d; 7.62s (–C₆H₃NO₂–), 3.03s (CH₃SO₂), 1.9s (CH₃CO). ¹³C NMR (100MHz, CDCl₃) δ (ppm) 154.58(C-1), 119.36 (C-2/6), 129.85 (C-3, C-5), 124.94 (C-4), 146.28 (C-7), 111.43 (C-8), 137.55 (C-9), 115.73 (C10) 118.33 (C11) 148.11 (C-12), 44.85 (C-13), 25.19 (C-14). Elemental Analysis for C₁₇H₁₈CuN₂O₉S: calculated/found C(41.67/41.83), H(3.70/3.55), N(5.72/5.61)

Zn (II) complex of Nimesulide (N-Zn)

Yield 77 %, off white solid melting point 230 °C FT-IR $\nu(4000-400\text{ cm}^{-1})$: $\nu(\text{CH=CH})$ 1487m, $\nu(\text{O=S=O})$, Stretching) 1315s, $\nu(\text{C-O})$ 1246s, $\nu(\text{C-N})$ 1150m, $\nu(\text{M-N})$ 513m. ¹H NMR (400MHz, CDCl₃) δ (ppm) 7.5m; 7.44m; 7.22m(–C₆H₅), 8.01d; 7.14d; 7.7s (–C₆H₃NO₂–), 3.19s (CH₃SO₂). ¹³C NMR (100MHz, CDCl₃) δ (ppm) 155.44 (C-1), 121.49 (C-2/6), 130.81 (C-3,C-5), 125.36 (C-4), 143.48 (C-7), 112.84 (C-8), 136.07 (C-9), 119.73 (C10) 119.97 (C11) 147.9 (C-12) and 41.30 (C-13). Elemental Analysis for C₂₆H₂₂N₄O₁₀S₂Zn: calculated/found C (45.92/45.77), H (3.26/3.41), N (8.24/8.11).

Fe (III) complex of Nimesulide (N-Fe)

Yield 65 %, brown solid melting point 105°C, FT-IR $\nu(4000-400\text{ cm}^{-1})$: $\nu(\text{CH=CH})$ 1480m, $\nu(\text{O=S=O})$, Stretching) 1337s, $\nu(\text{C-O})$ 1216s, $\nu(\text{C-N})$ 1125m, $\nu(\text{M-N})$ 526m, ¹H NMR (400MHz, CDCl₃) δ (ppm) 7.37m; 7.28m; 7.16m (–C₆H₅), 7.9d; 6.98d; 7.65s (–C₆H₃NO₂–), 3.1s (CH₃SO₂), ¹³C NMR (100MHz, CDCl₃) δ (ppm) 155.41 (C-1), 121.56 (C-2,C-6), 130.78 (C-3,C-5), 125.31 (C-4), 143.58 (C-7), 112.8 (C-8), 136.1 (C-9), 119.8 (C10), 120.05 (C11), 147.85 (C-12) and 41.25 (C-13). Elemental Analysis for C₂₆H₂₂ClFeN₄O₁₀S₂: calculated/found C (44.24/44.31), H (3.14/3.00), N(7.94/7.78).

SbCl₃ (III) complex of Nimesulide (N-Sb1)

Yield 83 %, white solid, melting point 128-132°C, FT-IR (4000-400cm⁻¹): $\nu(\text{CH=CH})$ 1483m, $\nu(\text{O=S=O})$, Stretching) 1333s, $\nu(\text{C-O})$ 1245s, $\nu(\text{C-N})$ 1149m, $\nu(\text{M-N})$ 514m. ¹H

NMR (400MHz, CDCl₃) δ (ppm) 7.26m; 7.41m; 7.46m (–C₆H₅), 8.04d; 7.16d; 7.75s (–C₆H₃NO₂–), 3.21s (CH₃SO₂), ¹³C NMR (100MHz, CDCl₃) δ (ppm) 155.49 (C-1), 121.53 (C-2,C-6), 130.81 (C-3, C-5), 125.35 (C-4), 143.54(C-7), 112.86 (C-8), 136.05 (C-9), 119.74 (C10), 120.0 (C11), 147.91 (C-12) and 41.34 (C-13). Elemental Analysis for C₂₆H₂₂ClN₄O₁₀S₂Sb: calculated/found C (40.46/40.26), H (2.87/2.75), N(7.26/7.51).

SbBr₃ (III) complex of Nimesulide (N-Sb2)

Yield 78%, light brown solid, melting point 105-109°C. FT-IR (4000-400cm⁻¹) $\nu(\text{CH=CH})$ 1487m, $\nu(\text{O=S=O})$, Stretching) 1315s, $\nu(\text{C-O})$ 1213s, $\nu(\text{C-N})$ 1127m, $\nu(\text{Sb-N})$ 511m, ¹H NMR (400MHz, CDCl₃) δ (ppm) 7.5m; 7.43m; 7.23m (–C₆H₅), 8.01d; 7.13d; 7.7s (–C₆H₃NO₂–), 3.19s (CH₃SO₂), ¹³C NMR (100MHz, CDCl₃) δ (ppm) 155.44 (C-1), 121.53 (C-2, C-6), 130.82 (C-3, C-5), 125.37 (C-4), 143.53 (C-7), 112.83 (C-8), 136.0 (C-9), 119.74 (C10), 119.98 (C11), 147.9(C-12), 41.38 (C-13). Elemental analysis for C₂₆H₂₂BrN₄O₁₀S₂Sb: calculated/ found C(38.26/38.37), H (2.72/2.89), N(6.86/6.73).

IN-VITRO ANTIBACTERIAL ACTIVITY

In-vitro Antifungal activity of the synthesized complexes and the parent drug Nimesulide was carried by agar well disc diffusion method^{19,20} keeping cefixime as positive control and DMSO as negative control. The activity was done against pathogenic strains of bacteria including Gram negative *Escherichia Coli* and Gram positive *Staphylococcus Aureus* using Nutrient agar medium (Merck).

ANTIFUNGAL ACTIVITY

Antifungal activity of the complexes was performed against the available fungal strains; *Aspergillus Flavous*, *Aspergillus Niger*, *Aspergillus Fumigatus*, *Fusarium Solani* and *Mucor SP* using Terbinafine as positive control and DMSO as negative control. Antifungal activity was evaluated by following the tube diffusion method^{21,22} using sabouraud dextrose agar (Merck).

RESULTS AND DISCUSSION

The difference in the physical states and melting points of the synthesized products and the parent drug nimesulide supports the formation of the metal complexes. Further justification was achieved with the performed elemental analysis. The found values of CHN are well in range of the calculated values. The infrared vibrational spectra of metal, nitrogen bonds of different metal complexes have been studied and reported in the literature, The metal–Nitrogen vibration band is observed in the range 450-550 cm⁻¹. The presence of metal nitrogen bond signal in the expected range justifies the formation of the synthesized metal complexes. The first evidence is the disappearance of the strong $\nu(\text{N-H})$ band due to the loss of hydrogen atom of parent drug upon coordination and the next is the shift of the vibrational bands to the lower energy values, which ultimately confirms the

complexation. In NMR the change in chemical shift signals of nimesulide and the synthesized complexes indicated the coordination of nimesulide to the metal ions. Observing the chemical shift values presented above it is also possible to note that all the hydrogens are shifted upfield upon coordination of the metal to the drug. The difference in the IR and NMR spectra of the parent drug and the synthesized complexes confirms the formation of the metal complexes of Nimesulide. Antifungal and antibacterial results of the synthesized complexes are given below in table 1 and table 2 and their graphical illustrations are given in the figure 2 and figure 3 respectively. Interestingly few of the synthesized complexes of nimesulide have shown impressive antibacterial and antifungal activities.

Table 1: Zone of Inhibition in mm against bacterial strains

Samples	<i>Staphylococcus Aureus</i>	<i>Escherichia coli</i>
N	0	0
N-Zn	13	15
N-Cu	0	9
N-Fe	0	6
N-Sb1	15	12
N-Sb2	7	9
DMSO	0	0
Control	21	22




Figure 2: Graphical Illustration of Antibacterial activity of Synthesized Metal Complexes

Table 2: Zone of Inhibition in mm against Fungal Strains

Sample s	<i>A. Flavous</i>	<i>A. Niger</i>	<i>F. Solani</i>	<i>A. Fum igatus</i>	<i>Muco r SP</i>
N	0	0	0	0	0
N-Zn	8	11	10	9	7
N-Cu	0	0	0	0	0
N-Fe	0	0	0	0	0
N-Sb1	0	0	0	0	0
N-Sb2	0	0	0	0	0
DMSO	0	0	0	0	0
Control	28	32	34	30	32




Figure 3: Graphical Illustration of Antifungal activity of Synthesized Metal Complexes

CONCLUSION

Zn(II), Cu(II), Fe(III) and Sb(III) complexes of nimesulide were successfully synthesized and characterized using various spectral techniques. Biological screening of the synthesized complexes proved to be fruitful as it has revealed that some of the complexes are more potent antibacterial and antifungal agents than the drug Nimesulide, which showed inert behaviour. Our future work involves the further investigation of the other pharmacological aspects of the synthesized metal complexes.

REFERENCES

- Bernareggi A, Rainsford K. Pharmacokinetics of nimesulide. In: Nimesulide—Actions and Uses: Springer; 2005. p. 63-120.
- Rainsford K, Bevilacqua M, Dallegri F, Gago F, Ottonello L, Sandrini G, Tassorelli C, Tavares I. Pharmacological properties of nimesulide. In: Nimesulide—Actions and Uses: Springer; 2005. p. 133-244.
- Singh A, Singh P, Kapoor VK. Nimesulide. Analytical profiles of drug substances and excipients. 2001;28:197-249.
- Rainsford K. The discovery, development and novel actions of nimesulide. In: Nimesulide—Actions and Uses: Springer; 2005. p. 1-49.
- de Paiva RE, Abbehausen C, Gomes AF, Gozzo FC, Lustrri WR, Formiga AL, Corbi PP. Synthesis, spectroscopic characterization, DFT studies and antibacterial assays of a novel silver (I) complex with the anti-inflammatory nimesulide. Polyhedron. 2012;36(1):112-119.
- Jones CJ, Thornback J. Medicinal applications of coordination chemistry: Royal Society of Chemistry; 2007.

7. Dabrowiak JC. *Metals in medicine*: John Wiley & Sons; 2009.
8. Reilly C. *The nutritional trace metals*: John Wiley & Sons; 2008.
9. Weder JE, Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Biffin J, Regtop HL, Davies NM. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. *Coordination Chemistry Reviews*. 2002;232(1):95-126.
10. Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Zhou Q, Davies NM, Biffin JR, Regtop HL. Gastrointestinal toxicity, antiinflammatory activity, and superoxide dismutase activity of copper and zinc complexes of the antiinflammatory drug indomethacin. *Chemical research in toxicology*. 2003;16(1):28-37.
11. Chohan ZH, Supuran CT, Scozzafava A. Metalloantibiotics: synthesis and antibacterial activity of cobalt (II), copper (II), nickel (II) and zinc (II) complexes of kefzol. *Journal of enzyme inhibition and medicinal chemistry*. 2004;19(1):79-84.
12. Beraldo H, Garnier-Suillerot A, Tosi L, Lavelle F. Iron (III)-adriamycin and iron (III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activity. *Biochemistry*. 1985;24(2):284-289.
13. Tiekink ER. Antimony and bismuth compounds in oncology. *Critical reviews in oncology/hematology*. 2002;42(3):217-224.
14. Khan NUH, Nadeem KSH. Synthesis, Characterization and Antibacterial Activity of New Antimony (III) Complexes of Some Tosyl-Sulfonamide Derivatives. *Middle-East Journal of Scientific Research*. 2013;16(8):1109-1115.
15. Kovala-Demertzi D, Staninska M, Garcia-Santos I, Castineiras A, Demertzis MA. Synthesis, crystal structures and spectroscopy of meclofenamic acid and its metal complexes with manganese (II), copper (II), zinc (II) and cadmium (II). Antiproliferative and superoxide dismutase activity. *Journal of Inorganic Biochemistry*. 2011;105(9):1187-1195.
16. Obaleye JA, Caira MR, Tella AC. Synthesis, characterization and crystal structure of a polymeric zinc (II) complex containing the antimalarial quinine as ligand. *J Chem Crystallogr*. 2007;37(10):707-712.
17. El-Sawaf AK, West DX, El-Saied FA, El-Bahnasawy RM. Synthesis, magnetic and spectral studies of iron (III), cobalt (II, III), nickel (II), copper (II) and zinc (II) complexes of 4-formylantipyrene N (4)-antipyrynylthiosemicarbazone. *Transition Met Chem*. 1998;23(5):649-655.
18. Lizarazo-Jaimes EH, Monte-Neto RL, Reis PG, Fernandes NG, Speziali NL, Melo MN, Frézard F, Demicheli C. Improved Antileishmanial Activity of Dppz through Complexation with Antimony (III) and Bismuth (III): Investigation of the Role of the Metal. *Molecules*. 2012;17(11):12622-12635.
19. IHSAN-UL-HAQ A, AHMED I, HUSSAIN I, JAMIL M, MIRZA B. Antibacterial activity and brine shrimp toxicity of *Artemisia dubia* extract. *Pak J Bot*. 2012;44(4):1487-1490.
20. Berhanu WM, Ibrahim MA, Pillai GG, Oliferenko AA, Khelashvili L, Jabeen F, Mirza B, Ansari FL, El-Feky SA, Katritzky AR. Similarity analysis, synthesis, and bioassay of antibacterial cyclic peptidomimetics. *Beilstein journal of organic chemistry*. 2012;8(1):1146-1160.
21. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. *Antimicrobial agents and chemotherapy*. 1987;31(9):1365-1368.
22. Gurgel LA, Sidrim J, Martins DT, Rao VS. In vitro antifungal activity of dragon's blood from *Croton urucurana* against dermatophytes. *Journal of ethnopharmacology*. 2005;97(2):409-412.